-+ 0.00%
-+ 0.00%
-+ 0.00%
NXERA Pharma announced that vamorolone has been selected as a pilot program to accelerate reimbursement for rare disease treatment in South Korea.
Share
Listen to the news
NXERA Pharma announced that vamorolone has been selected as a pilot program to accelerate reimbursement for rare disease treatment in South Korea.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending